NCT00128102View on ClinicalTrials.gov

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

PHASE3CompletedINTERVENTIONAL
Enrollment

661

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 15, 2011

Study Completion Date

November 21, 2011

Conditions
MesotheliomaLung Cancer
Interventions
DRUG

Vorinostat

Vorinostat 100 mg oral capsules

DRUG

Placebo

Vorinostat-matching placebo oral capsules

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00128102 - Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | Biotech Hunter | Biotech Hunter